EUVIMEDEUVIMED entdecken
Crossref

CAR-T Cell Therapies: An Emerging and Promising Treatment for Human Glioblastoma

Neha Nimma, Piper Levin, Emily Ricigliano, Sophia Shin, Leon Wang

Georgetown Scientific Research Journal · 01.06.2026 · 6 (2) · 73-84

DOI: 10.48091/sjkpxr59 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Georgetown Scientific Research Journal, online erschienen am 01.06.2026. Verfasst von Neha Nimma und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human glioblastoma (GBM) is the most lethal type of brain tumor. Current therapies struggle to effectively target the tumor, leading to high recurrence rates and poor survival outcomes. Chimeric antigen receptor T-cell (CAR-T) therapy, although new and evolving, has shown success in hematological malignancies such as leukemia and lymphoma, and is currently being adapted for GBM. This review discusses emerging clinical and preclinical studies that serve as evidence for both the advancements and limitations of CAR-T therapy for GBM treatment. While prior reviews have addressed individual aspects of CAR‑T therapy for GBM, this review explores how antigen selection, delivery strategy, and the tumor microenvironment collectively influence therapeutic outcomes. Tumor antigens have been used as therapeutic targets, each exhibiting differential expression patterns and distinct anti‑tumor activity. Next‑generation multivalent CAR‑T constructs, which simultaneously engage multiple antigens or pathways, have shown promise in addressing GBM’s heterogeneity and treatment resistance. Beyond antigen targets, delivery methods have also been found to play a crucial role in determining the success of this treatment. Cerebrospinal fluid and locoregional delivery show superior tumor penetration compared to typical intravenous delivery. Still, successful CAR-T engraftment faces major challenges, such as the immunosuppressive nature of the GBM microenvironment, the transient effects of CAR-T cells, and antigen loss. It is important to note that many findings discussed in this review are derived from small-scale Phase I clinical trials, which may limit the generalizability of the conclusions. Collectively, evidence indicates that CAR-T immunotherapy represents a promising, yet evolving, treatment with the potential to improve outcomes for patients with this malignant disease.

Zitieren

APA

Nimma, N., Levin, P., Ricigliano, E., Shin, S., & Wang, L. (2026). CAR-T Cell Therapies: An Emerging and Promising Treatment for Human Glioblastoma. Georgetown Scientific Research Journal, 6(2), 73-84. https://doi.org/10.48091/sjkpxr59

Vancouver

Nimma N, Levin P, Ricigliano E, Shin S, Wang L. CAR-T Cell Therapies: An Emerging and Promising Treatment for Human Glioblastoma. Georgetown Scientific Research Journal. 2026;6(2):73-84. doi:10.48091/sjkpxr59

BibTeX
@article{Nimma2026,
  author = {Nimma, Neha and Levin, Piper and Ricigliano, Emily and Shin, Sophia and Wang, Leon},
  title = {CAR-T Cell Therapies: An Emerging and Promising Treatment for Human Glioblastoma},
  journal = {Georgetown Scientific Research Journal},
  year = {2026},
  volume = {6},
  number = {2},
  pages = {73--84},
  doi = {10.48091/sjkpxr59}
}
Kostenlos starten →